ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, Roberts L, Tahir SK, Xiao Y, Yang X, Zhang H, Fesik S, Rosenberg SH, Elmore SW
Cancer Res. 2008 68 (9): 3421-8

PMID: 18451170 · DOI:10.1158/0008-5472.CAN-07-5836

MeSH Terms (25)

Administration, Oral Aniline Compounds Animals Antibodies, Monoclonal Antibodies, Monoclonal, Murine-Derived Antineoplastic Agents Carcinoma, Small Cell Cells, Cultured Drug Synergism Humans Lung Neoplasms Lymphoma, Mantle-Cell Mice Mice, Knockout Mice, SCID Models, Biological Neoplasms Precursor Cell Lymphoblastic Leukemia-Lymphoma Proto-Oncogene Proteins c-bcl-2 Rituximab Sulfonamides Thrombocytopenia Treatment Outcome Tumor Burden Xenograft Model Antitumor Assays

Connections (1)

This publication is referenced by other Labnodes entities:

Links